Fairscale Capital’s West Pharmaceutical WST Stock Holding History

Fairscale Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.49K	Buy	+23	New	+$8.12K	0.01%	325

Other funds holding WST

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return

Fairscale Capital's WST Position: Q3 2026 in Review

Fairscale Capital opened a new position in West Pharmaceutical (WST) in Q3 2026: 23 shares worth $9.49K. The stake represents 0.01% of the portfolio and ranks #325 among its holdings.

430 funds tracked by Wall St. Rank hold WST as of Q3 2026.

Fairscale Capital held 23 shares of West Pharmaceutical worth $9.49K as of Q3 2026.
West Pharmaceutical was a new Fairscale Capital position in Q3 2026.
West Pharmaceutical made up 0.01% of Fairscale Capital's portfolio in Q3 2026, its #325 holding.
430 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Fairscale Capital's 13F filing for Q3 2026, filed 4 Nov 2026.